1. Home
  2. ORIO vs NEUP Comparison

ORIO vs NEUP Comparison

Compare ORIO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ORIO

Orion Digital Corp. Common Shares

N/A

Current Price

$0.67

Market Cap

23.0M

Sector

N/A

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.42

Market Cap

23.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORIO
NEUP
Founded
N/A
1996
Country
Canada
United States
Employees
188
8
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
23.0M
23.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ORIO
NEUP
Price
$0.67
$3.42
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
27.8K
90.8K
Earning Date
03-12-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$74.52
N/A
Revenue Next Year
$5.07
N/A
P/E Ratio
$4.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$3.19
52 Week High
$1.40
$21.31

Technical Indicators

Market Signals
Indicator
ORIO
NEUP
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
ORIO
NEUP

About ORIO Orion Digital Corp. Common Shares

Orion Digital Corp is a financial technology company operating digital platforms across wealth and payments, supported by a consumer lending business in Canada. The Company's Wealth platform, Intelligent Investing, provides long-term investment solutions to the Canadian market. It also operates a consumer lending business in Canada. Its Payments business is conducted through its wholly owned subsidiary, which provides issuer processing, program management, and regulated payment orchestration services across Europe. The Company operates in Canada and Europe, with Canada generating the majority of its revenue.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: